Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Visium Technologies signs term sheet to transfer device rights into new Indonesian PMA unit

Visium Technologies signs term sheet to transfer device rights into new Indonesian PMA unit

BitgetBitget2026/09/21 20:20
  • Visium Technologies signed a non-binding term sheet to assign specified contract-use, offtake, and deployment rights into a new Indonesian PMA company.
  • A wholly owned Delaware unit would hold a 99% stake in the Indonesian vehicle.
  • The proposed deal is an asset assignment, not an acquisition of an operating company or semiconductor manufacturing business.
  • Closing remains conditional on key approvals and consents, including device specifications, export-control classification, Indonesian approvals, and Florida corporate approvals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Visium Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-26-008490), on September 21, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Novo Nordisk (NVO.US) Capital Markets Day underwhelms: CEO admits too many commitments, insufficient fulfillment, and the need to rebuild investor confidence

Novo Nordisk CEO Lars Fruergaard Jørgensen said in an interview on Tuesday that the company must make greater efforts to rebuild investor confidence, as its largest drug will face a patent cliff in the early part of the next decade.

智通财经2026/09/22 09:26